Grudén et al, Int. Journal of Pharmaceutics (2021) – Biodistribution of fluorescence-labelled EGF protein from slow release NanoZolid depots in mouse.
Klotz et al, European Urology Focus (2021) – Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients.
Grudén, Thesis for doctoral degree (Ph.D.) at Karolinska Institutet (2021) – Novel injectable calcium sulfate depot formulations for local cancer.
Grudén et al, Journal of Drug Delivery Science and Technology (2018) – Cold isostatic pressing of hydrating calcium sulfate as a means to produce parenteral slow-release drug formulations.
Tammela et al, The Journal of Urology, (2017) – An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
Grundén et el, European Journal of Pharmaceutics and Biopharmaceutics (2017) – Antitumoral effect and reduced systemic toxicity in mice after intratumoral injection of an in vivo solidifying calcium sulfate formulation with docetaxel.
Sjögren et al, Molecular Pharmaceutics (2014) – Pharmacokinetics of an Injectable Modified Release Hydroxyflutamide Formulation in the Human Prostate Gland Using a Semiphysiologically Based Biopharmaceutical Model.
The International Society for Magnetic Resonance in Medicine (2018) – Magnetic resonance spectroscopy of localized prostate cancer: assessment of antitumor effects of intra-prostatic hormone deprivation therapy.
Annual Congress of the European Association of Urology (2016) – An open, single dose, anti-tumour effect study of 2-hydroxyflutamide as a controlled release product (Liproca® Depot) injected into the prostate in patients with localized prostate cancer.
Annual Congress of the European Association of Urology (2014) – Local antiandrogen therapy, a novel treatment strategy for localized prostate cancer.
World Conference on Drug Absorption, Transport and Delivery (2013) – A semi-physiological biopharmaceutical model for simulation and prediction of 2-hydroxyflutamide concentrations in plasma and prostate tissue in prostate cancer patients following local administration of an injectable depot formulation.
Annual Congress of the European Association of Urology (2011) – Focal drug therapy, a novel treatment strategy for localized prostate cancer.